Positron-Emitting Huntingtin Probe for PET Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecular imaging techniques lack effective probes for early detection of Huntington's disease, which is characterized by the accumulation of aggregated huntingtin protein, making it difficult to initiate treatments at early stages and monitor disease progression effectively.
Innovation Solution
Development of a positron-emitting imaging agent comprising a compound of Formula I, or its pharmaceutically acceptable salt, labeled with one or more positron-emitting radionuclides, which binds specifically to huntingtin protein aggregates, enabling diagnostic imaging of Huntington's disease through PET imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current molecular imaging techniques are used, then general disease detection is possible, but detection of huntingtin protein aggregates in Huntington's disease is not achievable
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of imaging probes to create compounds with specific binding affinity for huntingtin protein aggregates. The invention involves synthesizing and evaluating various probe structures (e.g., compounds with different functional groups, linkers, and radiolabeling positions) to optimize binding characteristics, thereby enabling specific detection of HTT aggregates that was previously impossible with existing probes.
2Reliability
If treatments are initiated later in disease progression, then diagnostic uncertainty is reduced, but early intervention opportunities are lost
Solution Approach 1:
The patent enables preliminary action by providing imaging probes that can detect huntingtin protein aggregates at very early stages of Huntington's disease, potentially before clinical symptoms appear. This allows for early diagnosis and treatment initiation, transforming the clinical approach from reactive (after symptom onset) to proactive (before or at early disease stages), thereby preventing or slowing disease progression.
3Ease of manufacture
If existing imaging probes are used, then general molecular imaging is possible, but specific visualization of huntingtin aggregates is not achieved
Solution Approach 1:
The patent applies segmentation by dividing the imaging probe into distinct functional modules: a huntingtin-binding moiety (such as peptides or small molecules that specifically recognize HTT aggregates), a linker region, and a radiolabeling position. This modular design allows for systematic optimization of each component's function while maintaining overall probe synthesizability and target specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The imaging agent allows for sensitive and specific visualization of huntingtin protein aggregates in the brain, facilitating early detection and monitoring of Huntington's disease progression, thereby aiding in timely intervention and clinical trial participant selection.
Implementation Method 1
PET involves the administration to a subject of a positron-emitting radionuclide tracer followed by detection of the positron emission (annihilation) events in the body
Implementation Method 2
detection of the positron emission (annihilation) events
Implementation Method 3
positron emission (annihilation) events
Data Source
AI summary
Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.